Puniska Healthcare

What Puniska Healthcare does

Puniska Injectables is a privately-owned Indian pharmaceutical manufacturer specializing in parenteral and injectable sterile products using Blow-Fill-Seal (BFS) aseptic technology. The company operates a state-of-the-art manufacturing facility in Goa equipped with five automatic BFS production lines producing terminally sterilized products in pack sizes ranging from 100ml to 1000ml, with corporate headquarters in Ahmedabad. Its portfolio consists of 27 distinct formulations organized across common solutions (dextrose, sodium chloride, multiple electrolytes, Ringer's lactate) and anti-infective injectables (Ciprofloxacin, Metronidazole), all manufactured under a Quality by Design framework. The company is led by founder Kalpesh Patel (32+ years of industrial experience), co-founder Shalin Patel, and head strategist Karan Patel.

The business model is anchored in direct B2B sales of pharmaceutical products, primarily to government healthcare authorities in India for supply to the public healthcare system. Pricing is quote-based and undisclosed, typical for government tender-driven commodity injectable markets. The company pursues international market expansion through regulatory approvals and registrations from agencies worldwide, targeting both semi-regulated and regulated markets. Quality management is reinforced through a Global Quality Metrics System with statistical analysis of selected quality indicators for continuous improvement. The company operates as the healthcare division of Puniska Group of Companies, a privately-held diversified group also engaged in real estate and financial investments.

Name

Puniska Healthcare

Legal name

Puniska Injectables

Website

https://puniska.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Injectables and Infusions Sales: Manufacture and sale of parenteral products including common solutions (dextrose, electrolytes, diuretics) and anti-infectives to domestic and international markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Puniska Injectables manufactures parenteral, infusion, and injectable sterile pharmaceutical products using Blow-Fill-Seal (BFS) aseptic technology at its Goa, India facility. The portfolio spans 27 formulations including dextrose solutions, sodium chloride (normal saline), compound sodium lactate (Ringer's lactate), multiple electrolytes with dextrose (PSKLYTE), paracetamol infusion, and anti-infectives such as ciprofloxacin and metronidazole, supplied primarily to government healthcare authorities in India and select international markets.

Product overview

Puniska Injectables is a privately-owned pharmaceutical company specializing in the development and manufacturing of parenteral products including injectable sterile solutions and IV infusions. The company operates as part of Puniska Group of Companies and serves semi-regulated markets worldwide. The product portfolio consists of 27 distinct pharmaceutical formulations organized into four main categories: (1) Dextrose Injections in various concentrations (5%, 10%, 25%) and pack sizes (100ml to 1000ml), including standard and Enhanced Handling (EH) variants; (2) Sodium Chloride (Normal Saline) Injections at 0.9% concentration across multiple pack sizes; (3) Combined Dextrose and Sodium Chloride Solutions (DNS) and Compound Sodium Lactate (Ringer's Lactate); (4) Multiple Electrolytes and Dextrose Injections (PSKLYTE-M and PSKLYTE-P) for balanced IV hydration; and (5) Anti-infective injectables including Ciprofloxacin and Metronidazole. All products are manufactured using blow-fill-seal (BFS) technology and aseptic processing at the company's Goa, India facility.

Differentiator

Problem solved

Functional benefit

Products and services

• Dextrose Injections Sterile intravenous dextrose solutions available in 5%, 10%, and 25% w/v concentrations across 100 ML, 250 ML, 500 ML, and 1000 ML pack sizes, including Enhanced Handling (EH) variants. Manufactured using BFS aseptic technology for hydration and caloric support in clinical settings.
• Sodium Chloride Injections (Normal Saline) 0.9% w/v sodium chloride intravenous solutions in 100 ML, 250 ML, 500 ML, and 1000 ML pack sizes, including EH (Enhanced Handling) variants. Manufactured using BFS aseptic technology for fluid and electrolyte replenishment in hospitals and clinics.
• Dextrose and Sodium Chloride (DNS) Injections Combined 5% dextrose and 0.9% sodium chloride IV solutions for combined hydration and electrolyte supply, available in 250 ML, 500 ML, and 1000 ML pack sizes (including EH variants). Manufactured using BFS aseptic technology.
• Compound Sodium Lactate Injection (Ringer's Lactate) Ringer's lactate IV solutions for fluid replacement and electrolyte balance, available in 250 ML, 500 ML, and 1000 ML pack sizes. Manufactured using BFS aseptic technology for surgical, trauma, and critical care use.
• Multiple Electrolytes and Dextrose Injections (PSKLYTE-M and PSKLYTE-P) Balanced electrolyte solutions with dextrose for IV hydration in Type I (PSKLYTE-P) and Type III (PSKLYTE-M) formulations, available in 250 ML, 500 ML, and 1000 ML pack sizes. Manufactured using BFS aseptic technology for clinical hydration therapy.
• Paracetamol Infusion (PSK-PARAMOL) 1% w/v paracetamol IV infusion in 100 ML pack for analgesic and antipyretic use in clinical settings. Manufactured using BFS aseptic technology.
• Ciprofloxacin Injection IP 2 mg/mL Fluoroquinolone antibiotic injection in 100 ML pack for treating susceptible bacterial infections. Manufactured using BFS aseptic technology for hospital antibiotic therapy.
• Metronidazole Injection IP 0.5% w/v Antiprotozoal and antibacterial injection in 100 ML pack for treatment of anaerobic bacterial infections. Manufactured using BFS aseptic technology.
• Half-Strength Saline with Dextrose Injection (0.45% NaCl & 5% Dextrose) 0.45% sodium chloride with 5% dextrose IV solution in 500 ML pack for combined hypotonic fluid and electrolyte therapy. Manufactured using BFS aseptic technology.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Claris Lifesciences: Indian specialty sterile injectables manufacturer with similar focus on hospital IV fluids, parenteral nutrition and anti-infectives, directly comparable in product mix, regulatory positioning and target customers.
• Aculife Healthcare: Indian manufacturer of large-volume parenterals (LVP) and IV fluids, directly comparable product portfolio of saline, dextrose and electrolyte solutions sold to hospitals and government channels.
• Akums Drugs & Pharmaceuticals: One of India's largest contract manufacturers of injectables and oral dosage forms; comparable product categories (sterile injectables, IV fluids) and similar B2B/government go-to-market with Indian manufacturers.
• BDR Pharmaceuticals: Indian sterile injectables manufacturer with focus on anti-infectives, oncology and hospital injectables; directly comparable in product mix and customer base targeting Indian hospitals and government.
• Bharat Serums and Vaccines: India-based sterile injectables and biological products company with overlapping focus on hospital injectables, plasma products and anti-infectives; comparable customer segments in Indian hospital and government channels.

Broad incumbents

• B. Braun Medical India: Subsidiary of global medical device and IV solutions leader B. Braun; competes with Puniska in IV fluids and infusion therapy but operates at much larger scale across regulated and emerging markets.
• Fresenius Kabi India: Global IV fluids, parenteral nutrition and injectable drugs major with substantial India manufacturing footprint; overlaps with Puniska in dextrose, saline and electrolyte solutions across hospital and government channels.
• Baxter India: Multinational leader in IV solutions, parenteral nutrition and infusion systems; operates India manufacturing and competes with Puniska for hospital and government contracts in standard IV fluids.
• Emcure Pharmaceuticals: Large Indian pharmaceutical manufacturer with significant injectables portfolio across multiple therapy areas; broader portfolio and global presence than Puniska but competes in overlapping sterile injectable categories.
• Piramal Pharma Solutions: Global CDMO with sterile injectables manufacturing capabilities including India facilities; comparable in aseptic manufacturing technology and injectable offerings, though operates at significantly larger scale with a broader services portfolio.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Puniska Healthcare